CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing -HAMPTON, N.J., ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Binding and crosslinking experiments demonstrate that this protein is the receptor for a recently described interleukin 7 (IL-7)-like factor, thymic stromal lymphopoietin (TSLP). Binding of TSLP ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal antibody against ...

The following is a summary of "Vascular Remodeling and TSLP/Angiogenin Overexpression in Severe Mixed Asthma," published in the February 2025 issue of the Respiratory Research by Bertolini et al.

Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal ...

Thymic stromal lymphopoietin (TSLP) is an interleukin-7-like cytokine that is associated with the pathology of atopic dermatitis and asthma. Although the role of this cytokine has been studied in ...

Thymic stromal lymphopoietin (TSLP) is an important target associated with autoimmune diseases, various allergic conditions, chronic inflammation, and cancer. To facilitate the development of drugs ...

The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over ...

HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non ...